Heart failure & cardiomyopathies
Fluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial
Authors' conclusion
In this pilot trial, the Reprieve System safely produced significantly faster decongestion compared with ODT.
Study context
- Population
- Hospitalized patients with acute HF96 received randomized treatment
- Participants
- 100 patients
- Comparison
- Reprieve System vs optimal diuretic therapy
- Reprieven = 52
- Optimal diuretic therapy (ODT)n = 44reference
- Primary endpoint
- 24-hour natriuresis (efficacy); composite of dialysis or doubling of creatinine, severe electrolyte abnormalities, hypotension or hypertensive emergency (safety)
- Follow-up
- 24 hours
Methodological detailspilot
- Pilot
Primary result
As reported in the abstract
24-hour natriuresis
P < 0.001
Further findings
IV diuretic therapy duration
P = 0.014
Rate of weight loss, net fluid loss, net natriuresis
- Rate of weight loss significantly faster with Reprieve
- P = 0.002
- Net fluid loss significantly faster with Reprieve
- P = 0.03
- Net natriuresis significantly faster with Reprieve
- P < 0.001
Safety
Primary safety composite (dialysis or doubling of creatinine, severe electrolyte abnormalities, hypotension, hypertensive emergency)
P = 0.42
| Outcome | Reprieve | ODT | P value |
|---|---|---|---|
| Change in serum creatinine | 0.19 ± 0.24 mg/dL | 0.31 ± 0.39 mg/dL | P = 0.07 |
Original publication
Fluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial. JACC Heart Fail. Published 1 May 2026. doi:10.
Summarised from the published abstract; every number is checked against it